Sanofi

U.S. stocks were mostly higher on the final trading day of May, as both the S&P 500 and Dow indices close at record highs, despite disappointing consumer spending data reported on Friday morning. Loretta Mester, the soon to be Cleveland Fed President argued in a speech the importance of...

The earnings crunch continues this week. Among the highlights will be scheduled quarterly reports from Exxon Mobil and Chevron, from Bristol-Myers Squibb and Merck, from Time Warner and Viacom, and also from Twitter. Early Thursday, Exxon Mobil (NYSE: XOM) is expected to say that it had earnings...

In a period when many biotech stocks were slipping, short sellers moved on many of the leading biotech and emerging pharmaceuticals between the March 14 and March 31 settlement dates. But Amgen (NASDAQ: AMGN), Celgene (NASDAQ: CELG) and Dendreon (NASDAQ: DNDN) were among those that bucked the...

U.S. stocks rebounded from a two-day losing streak as investors found plenty of positives in consumer confidence data which hit a six-year high in March. According to the Fed's Philadelphia chief Charles Plosser the Fed sees its bond purchasing program ending in October or November with rate...

U.S. stocks fell steeply on Friday as Wall Street recorded its first monthly loss since August. Investors have plenty on their plate to worry about from emerging markets, an earning season failing to ignite excitement and a lackluster consumer confidence that is being felt by many retailers who...

The number of shares sold short in leading biotech and emerging pharmaceutical companies mostly declined between the December 13 and December 31 settlement dates. BioMarin Pharmaceutical (NASDAQ: BMRN), Celgene (NASDAQ: CELG) and Dendreon (NASDAQ: DNDN) led that trend. Short sellers also shied...

Don’t expect to get a direct answer from any of the big pharma firms, but in the world of big data, the answer, or something pretty close to answer, was found by doing some simple math. Last year, Forbes columnist Matthew Herper went back to the basics and simply divided each company’s spending...

Oppenheimer has a new team of analysts focused on biotechnology and specialty pharmaceuticals. And, research from the new team includes recommendations to buy shares of Antares Pharma (NASDAQ: ATRS), Intercept Pharmaceuticals (NASDAQ: ICPT), Questcor Pharmaceuticals (NASDAQ: QCOR) and ViroPharma...

It is not unusual for stocks on a tear to overrun their mean price targets, which is a signal of how far analysts on average expect the share price to climb. Some of the top-performing health care stocks over the past six months that pay dividends, such as Becton, Dickinson (NYSE: BDX), Bristol-...

Eli Lilly (NYSE: LLY), which last week announced a deal to buy two imaging agents from Siemens (NYSE: SI) that could help aid the fight against Alzheimer's, is scheduled to report its first-quarter 2013 results Wednesday, April 24, before the markets open. Investors will be watching for the latest...

Some smaller health care companies saw unusual movement in their stocks on Friday. And not just in Anacor Pharmaceuticals (NASDAQ: ANAC), Halozyme Therapeutics (NASDAQ: HALO), Puma Biotechnology (NYSE: PBYI) and Questcor Pharmaceuticals (NASDAQ: QCOR), which are discussed below. But also ACADIA...

Here is a quick look three top-performing biotech stocks with a consensus recommendation of analysts of Strong Buy. They are Medivation (NASDAQ: MDVN), Synageva BioPharma (NASDAQ: GEVA) and Optimer Pharmaceuticals (NASDAQ: OPTR). Medivation This San Francisco-based biopharmaceutical company...